Company Overview - As of March 28, 2025, Haobo Bio (688656) closed at 89.0 CNY, a slight increase of 0.02% from the previous week [1] - The company's total market capitalization is 5.612 billion CNY, ranking 57th out of 124 in the medical device sector and 2625th out of 5139 in the A-share market [1] Upcoming Events - Haobo Bio will hold its 2024 Annual General Meeting on April 7, 2025, in Suzhou, Jiangsu Province [1][3] - The meeting will review several proposals, including the 2024 annual report, financial budget for 2025, and the profit distribution plan for 2024 [1][3] Financial Performance - In 2024, the company achieved total operating revenue of 402.34 million CNY, representing a year-on-year growth of 2.01% [2][3] - The net profit attributable to shareholders was 36.80 million CNY, reflecting a decline of 22.24% compared to the previous year [2][3] Profit Distribution - The profit distribution plan for 2024 includes a cash dividend of 3.0 CNY per 10 shares, totaling 18.68 million CNY [2][3] Financial Plans - The company plans to apply for a bank credit facility not exceeding 700 million CNY for 2025 and anticipates a guarantee limit of no more than 200 million CNY [2][3]

证券代码：688656 证券简称：浩欧博 公告编号：2025-019 江苏浩欧博生物医药股份有限公司 关于变更双润正安信息咨询（北京）有限公司要约收购公司 持续督导财务顾问主办人的公告 董事会 江苏浩欧博生物医药股份有限公司（以下简称"公司"）于近日收到中国国际 金融股份有限公司（以下简称"中金公司"）发来的《关于变更双润正安信息咨询 （北京）有限公司要约收购江苏浩欧博生物医药股份有限公司持续督导财务顾问主 办人的函》。中金公司作为双润正安信息咨询（北京）有限公司要约收购公司（以 下简称"本项目"）的财务顾问，目前处于持续督导阶段。原财务顾问主办人马可 先生因个人工作变动原因已从中金公司离职，无法继续作为财务顾问主办人履行相 应职责。 本次变更后，本项目的持续督导财务顾问主办人为刘尚泉、邢宏远、高梦璇， 本次财务顾问主办人的变更不会对持续督导工作的质量和进度产生影响，财务顾问 团队将严格按照《上市公司收购管理办法》等相关法律法规的要求，认真履行财务 顾问职责，确保督导工作的连续性和有效性。 特此公告。 江苏浩欧博生物医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大 ...

中国国际金融股份有限公司 关于 双润正安信息咨询（北京）有限公司 要约收购江苏浩欧博生物医药股份有限公司 之 2024 年度持续督导意见 中国国际金融股份有限公司（以下简称"中金公司"、"本财务顾问"）接受收购人双 润正安信息咨询（北京）有限公司（以下简称"收购人"、"双润正安"）委托，担任其要 约收购江苏浩欧博生物医药股份有限公司（以下简称"上市公司"、"浩欧博"）之财务顾 问，持续督导期为要约收购报告书公告日起至要约收购完成后的 12 个月止，即 2024 年 12 月 20 日至 2026 年 2 月 14 日。根据相关法律法规规定，本财务顾问出具 2024 年度 （即 2024 年 12 月 20 日至 2024 年 12 月 31 日，以下简称"本持续督导期"）的持续督导 意见。 一、交易资产的交付或过户情况 经核查，本财务顾问认为：本持续督导期内，浩欧博、双润正安及其一致行动人按 照中国证监会有关上市公司治理和上海证券交易所规则的要求规范运作，依法行使股东 权益、履行股东义务。 2024 年 10 月 30 日，浩欧博控股股东海瑞祥天生物科技（集团）有限公司（以下 简称"海瑞祥天"）及其一致行动人 ...

特此公告。 江苏浩欧博生物医药股份有限公司 董事会 关于变更双润正安信息咨询（北京）有限公司要约收购公司 持续督导财务顾问主办人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）于近日收到中国国际 金融股份有限公司（以下简称"中金公司"）发来的《关于变更双润正安信息咨询 （北京）有限公司要约收购江苏浩欧博生物医药股份有限公司持续督导财务顾问主 办人的函》。中金公司作为双润正安信息咨询（北京）有限公司要约收购公司（以 下简称"本项目"）的财务顾问，目前处于持续督导阶段。原财务顾问主办人马可 先生因个人工作变动原因已从中金公司离职，无法继续作为财务顾问主办人履行相 应职责。 本次变更后，本项目的持续督导财务顾问主办人为刘尚泉、邢宏远、高梦璇， 本次财务顾问主办人的变更不会对持续督导工作的质量和进度产生影响，财务顾问 团队将严格按照《上市公司收购管理办法》等相关法律法规的要求，认真履行财务 顾问职责，确保督导工作的连续性和有效性。 证券代码：688656 证券简称：浩欧博 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook with expected revenue growth and profit recovery in the coming years [1]. Core Insights - The company achieved a revenue of 402 million yuan in 2024, reflecting a year-over-year growth of 2.01%, while the net profit attributable to the parent company was 37 million yuan, down 22.24% year-over-year [1][2]. - The traditional IVD business is stable, and new business investments are increasing, leading to short-term profit pressure. The revenue from allergy reagent products was 212 million yuan (up 0.46% YoY), and from autoimmune reagent products was 154 million yuan (up 3.42% YoY) [2]. - The company is expanding into desensitization drugs and has partnered with China National Pharmaceutical Group to create a comprehensive precision diagnosis and treatment ecosystem [2]. - Revenue forecasts for 2025-2027 are projected at 451 million, 507 million, and 574 million yuan, with corresponding net profits of 47 million, 60 million, and 77 million yuan, indicating significant growth rates [2][3]. Financial Summary - In 2024, the company reported a gross margin of 63.92%, an increase of 1.80 percentage points year-over-year. The management expense ratio was 16.31%, and the sales expense ratio was 23.43% [2]. - The company’s total revenue for 2023 was 394 million yuan, with a growth rate of 23.1%. The projected revenue for 2025 is 451 million yuan, with a growth rate of 12.2% [3]. - The earnings per share (EPS) for 2024 is projected at 0.58 yuan, with a price-to-earnings (P/E) ratio of 154.55 [3].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook for future revenue and profit growth, suggesting a favorable investment perspective [1][2]. Core Viewpoints - The company achieved a revenue of 402 million yuan in 2024, representing a year-over-year growth of 2.01%, while the net profit attributable to the parent company was 37 million yuan, down 22.24% year-over-year [1][2]. - The traditional IVD business is stable, with significant contributions from allergy and autoimmune testing product lines, while new business investments are expected to pressure short-term profits [2]. - The company is expanding its product pipeline in allergy detection and autoimmune disease testing, collaborating with China National Pharmaceutical Group to develop desensitization drugs, which aligns with its goal of creating a comprehensive diagnostic and treatment ecosystem [2]. - Revenue forecasts for 2025-2027 are projected at 451 million, 507 million, and 574 million yuan, with corresponding net profits of 47 million, 60 million, and 77 million yuan, indicating growth rates of 12.2%, 12.2%, and 13.4% respectively [2][3]. Financial Summary - In 2024, the company reported a gross margin of 63.92%, an increase of 1.80 percentage points year-over-year, despite a decline in net profit due to increased investment in new business and rising operational costs [2][3]. - The management expense ratio was 16.31%, up 4.83 percentage points year-over-year, while the sales expense ratio was 23.43%, down 0.42 percentage points year-over-year [2]. - The company’s earnings per share (EPS) for 2024 was 0.58 yuan, with a projected P/E ratio of 154.55 for the same year [3].

浩欧博: 江苏浩欧博生物医药股份有限公司2024年 年度股东大会会议资料 江苏浩欧博生物医药股份有限公司（688656） 2024 年年度股东大会会议资料 江苏浩欧博生物医药股份有限公司 二〇二五年四月 江苏浩欧博生物医药股份有限公司（688656） 2024 年年度股东大会会议 资料 江苏浩欧博生物医药股份有限公司（688656） 2024 年年度股东大会会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》以及《江苏浩欧 博生物医药股份有限公司章程》（以下简称"《公司章程》"）、《江苏浩欧博生物医药 股份有限公司股东大会议事规则》等相关规定，江苏浩欧博生物医药股份有限公司（以 下简称"公司"）特制定 2024 年年度股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员将 对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，出席会 ...

江苏浩欧博生物医药股份有限公司（688656） 2024 年年度股东大会会议资料 江苏浩欧博生物医药股份有限公司 2024 年年度股东大会会议资料 二〇二五年四月 | 2024 | 年年度股东大会会议须知 | 2 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 4 | | 2024 | 年年度股东大会会议议案 | 6 | | | 议案一： | 6 | | | 关于《公司 2024 年年度报告》及其摘要的议案 | 6 | | | 议案二： | 7 | | | 关于《公司董事会 2024 年度工作报告》的议案 | 7 | | | 议案三： | 15 | | | 关于《公司监事会 2024 年度工作报告》的议案 | 15 | | | 议案四： | 19 | | | 关于《公司 2024 年度财务决算报告》的议案 | 19 | | | 议案五： | 22 | | | 关于《公司 2025 年度财务预算计划》的议案 | 22 | | | 议案六： | 23 | | | 关于《公司 2024 年年度利润分配方案》的议案 | 23 | | | 议案七： | 24 | | | 关于公 ...

Group 1: Company Guarantees - The company provides guarantees for its wholly-owned subsidiaries to enhance overall financing efficiency, aligning with operational needs [1][2] - The total amount of guarantees provided to subsidiaries is RMB 200 million, accounting for 24.63% of the latest audited net assets and 19.36% of total assets [2] Group 2: Fundraising and Usage - The company raised a total of RMB 555.86 million through its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [5][6] - As of December 31, 2024, the company has strictly adhered to its fundraising management policies, ensuring funds are stored in dedicated accounts and used appropriately [7][8] Group 3: Fund Management and Investment - The company has not used idle fundraising for temporary working capital or to repay bank loans as of December 31, 2024 [9][11] - The company has approved the use of up to RMB 200 million of temporarily idle funds for cash management, ensuring safety and liquidity [9][10] Group 4: Project Updates - The company has decided to conclude certain fundraising projects and extend the timeline for others, specifically the "New In Vitro Diagnostic Reagent R&D Center Project" to September 2025 [12][13] - There are no changes in the use of funds for fundraising projects as of December 31, 2024 [14] Group 5: Compliance and Verification - The company has received positive verification from its accounting firm regarding the management and usage of fundraising, confirming compliance with relevant regulations [16][17]

二〇二四年度 "您可使用手机"扫一扫" 成进入"牲骑用手证明该和计报告是否由奥有快业许可的会计师排 新闻网 gosol）"扫一扫" 成进入"挂哪会计师行业统一监管平台（http://w.ng68gscs.g _ 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 内部控制审计报告 信会师报字[2025]第 ZA10174 号 江苏浩欧博生物医药股份有限公司 内部控制审计报告 江苏浩欧博生物医药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了江苏浩欧博生物医药股份有限公司(以下简称江 苏浩欧博公司)2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定,建立健全和有效实施内部控制,并评 价其有效性是江苏浩欧博公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的 有效性发表审计意见,并对注意到的非财务报告内部控制的重 ...